Sumary of Early data from CAR macrophage trial show cell therapy is safe, feasible for solid tumors:
- November 17, 2021 3 min read Source/Disclosures Published by: Source: Reiss KA, et al.
- Abstract 951. Presented at: Society for Immunotherapy of Cancer Annual Meeting;
- Reiss reports advisory board roles with or research funding from Bristol Myers Squibb, Carisma Therapeutics, Clovis Oncology, Eli Lilly, GlaxoSmithKline and Tesaro.
- Back to Healio Three patients have been safely treated with CT-0508, a novel cell-based therapy, according to initial results of a phase 1 trial presented at Society for the Immunotherapy of Cancer Annual Meeting.
- CT-0508 (Carisma Therapeutics) is an autologous, gene-edited chimeric antigen receptor macrophage therapy that targets the HER2 protein in tumor cells.
- The characteristics of macrophages and how they engage with tumors differs from that of T cells, which makes CAR macrophage therapy “a different modality” than CAR T cells, Kim A.
- Reiss, MD, assistant professor of medicine in the division of hematology/oncology at Perelman School of Medicine at University of Pennsylvania, told Healio.
- “CAR [macrophage] cells are highly present in the tumor microenvironment, and this particular product takes advantage of unique macrophage capabilities,” Reiss said.